

# Phenotypic and molecular characterization of resistance to macrolides and Lincosamides in *Corynebacterium striatum* clinical strains isolated from Tunisia

Sana Alibi<sup>1,2\*</sup>, Asma Ferjani<sup>3</sup>, Jalel Boukadida<sup>4</sup> and Jesus Navas<sup>2</sup>

<sup>1</sup>Research Unit Analysis and Process Applied to the Environment (UR17ES32)- Higher Institute of Applied Sciences and Technology, Mahdia, Tunisia

<sup>2</sup>Department of Molecular Biology, Faculty of Medicine, University of Cantabria, Spain

<sup>3</sup>Research Laboratory Resistance to Antibiotics, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia

<sup>4</sup>Laboratory of Microbiology-Immunology, Research Unit UR12SP34, University Hospital F. Hached, Sousse, Tunisia

## Abstract

**Objectives:** In this study we investigated the susceptibility profiles against macrolides and lincosamides of 85 *C. striatum* strains isolated at a clinical centre in Sousse (Tunisia).

**Methods:** The strains were identified by the routine biochemical assays and then confirmed by Vitek-Maldi-Tof-MS. MIC's of erythromycin and clindamycin were determined using the microdilution method. The detection of *erm(X)*, *erm(B)*, *msr(A)*, *mph(A)* and *mef(A-E)* resistance genes was performed by PCR. The strains were typed by PFGE using *XbaI*.

**Results:** Sixty-nine (81.17%) strains were resistant to erythromycin, 58 (67.44%) strains were resistant to clindamycin. There was a high correlation between the resistance to erythromycin and clindamycin and the presence of *erm(X)* gene in 85.50% and 89.65% respectively. The *erm(B)* gene was detected in 21(24.70%) strains whereas, no others genes were detected in our strains collection. By PFGE, the 85 strains belonged to 18 different clones.

**Conclusion:** *erm(X)* is implicated in macrolide resistance for almost all the *Corynebacterium* strains analyzed in our study. Other resistance genes like *erm(B)* must also be implicated in this resistance, although its presence seems to be unusual in previously reported studies.

## Introduction

*Corynebacterium striatum* is an ubiquitous microorganism of the human skin and mucous membranes. However, it is a significant emerging opportunistic pathogen causing serious infections in immunocompromised and hospitalized patients and isolated as the etiological factor of various infections such as pneumonia vertebral osteomyelitis septicemia and endocarditis [1-4]. Different studies showed high resistance rates against several antimicrobials and many outbreaks of multidrug resistant *C. striatum* have been recently reported [5,6]. Macrolides are frequently used in infections that can be caused by these microorganisms and are an alternative to  $\beta$ -lactams and tetracycline. They act by binding to the 50S subunits of bacterial ribosomes and interfere with protein synthesis by inhibiting the elongation of peptide chains [7]. Macrolide resistance in *C. striatum* is of particular interest because it is clearly an acquired phenotype and is common in clinical isolates. In *C. striatum*, resistance to macrolides was previously shown to be mainly due to methylase enzymes that are codified by *erm* genes.

Other resistance mechanisms such as mutations in 23S rRNA domain V, modifications of proteins L4 and L22, efflux pump systems, and hydrolytic enzymes have been reported in different genera [8,9]. Several studies reported high levels of resistance to macrolides among *Corynebacterium* species [10,11,12]. However, in Tunisia, no data are available. Therefore, we investigated the susceptibility profiles against

macrolides and lincosamides of 85 *C. striatum* strains isolated at a clinical centre in Sousse (Tunisia).

## Materials and methods

### Bacterial strains

We tested 85 *C. striatum* strains isolated from different specimens of patients presented at the laboratory of microbiology at the tertiary Hospital F. Hached Sousse, Tunisia, between January 2007 and December 2012. In this study, one isolate per patient was used. Strains were identified using a phenotypic method with the API Coryne system (bioMérieux) according to the manufacturer's instructions and by comparison with the API WEB database. Strains were also identified using a MALDI-TOF/ VITEK MS mass spectrometry system (bioMérieux). Obtained spectra were analyzed with the VITEK MS database.

**\*Correspondence to:** Sana Alibi, Research Unit Analysis and Process Applied to the Environment (UR17ES32)- Higher Institute of Applied Sciences and Technology, Mahdia, Tunisia, E-mail: alibi\_sana@hotmail.fr

**Key words:** *Corynebacterium striatum*, macrolide, Lincosamide, resistance, *erm* genes, PFGE

**Received:** November 21, 2019; **Accepted:** December 09, 2019; **Published:** December 13, 2019

### Antimicrobial susceptibility testing

In the screening tests for all investigated strains, inducible type of MLSB resistance was tested. Antibiotic discs (Biorad) of erythromycin (E - 15 mg) and clindamycin (Cln- 2 mg) were placed 15–20mm from each other on the on cation-adjusted Mueller-Hinton agar with 5% sheep blood and inoculums of 1.0 McFarland. The plates were incubated for 48 hours at 35°C. The appearance of a flattening zone around the clindamycin confirmed the presence of inducible resistance. In the case that approved breakpoints for *Corynebacterium spp.* were absent, criteria for MLSB antibiotics for *Staphylococcus spp.* were used. The susceptibility to erythromycin and clindamycin was also investigated using microdilution method in cation adjusted Muller-Hinton broth in accordance with guidelines of the Clinical and Laboratory Standards Institute (CLSI). The minimum inhibitory concentration (MIC) was estimated according to the CLSI guidelines for *Corynebacterium spp.* In the absence of approved breakpoints for *Corynebacterium spp.* breakpoints reported for *Staphylococcus spp.* were used. *C. striatum* (ATCC 6940), *C. jeikeium* (ATCC 43734), *E. coli* (ATCC 25922) and *S. pneumoniae* (ATCC 49619) and *S. aureus* (ATCC 29213) strains were used as controls. The strains were grown on blood agar plates during 24–48 hours at 37°C in normal atmosphere and checked for purity.

### Nucleic acid extraction and PCR

Few colonies were suspended in 200 ml of Instagene matrix (Biorad). The bacterial suspension was incubated during 15 minutes at 56°C followed by 8 minutes at 100°C and subsequently centrifuged at 12,000 rpm for 3 minutes. Supernatant was used for PCR studies. PCR was performed using commercial KAPA2G Fast HotStart Ready Mix (2X). The primers used for detection of the *erm(X)* gene were Cerm 1 (5'-GAC ACG GCC GTC ACG AGC AT-3') and Cerm 2 (5'-GGC GGC GAG CGA CTT CC- 3'); for the *erm(A)* gene: Erm A-1 (5'-TCT AAA AAG CAT GTA AAA GAA-3') and Erm A-2 (5'-CTT CGA TAG TTT ATT AAT AGT-3'); for the *erm(B)* gene: Erm B-1 (5'-GAA AAG GTA CTC AAC CAA ATA-3') and Erm B-2 (5'-AGT AAC GGT ACT TAA ATT GTT TAC-3'); and for the *mef(A-E)* gene: Mef A-E-1 (5'-AGT ATC ATT ATT CAC TAG TGC-3') and Mef A-E-2 (5'-TTC TTC TGG TAC TAA AAG TGG-3') and for the *mph(A)* gene: MphA-1(5'-AAC TGT ACG CAC TTG C-3') and MphA-2 (5'-GGT ACT CTT CGT TAC C-3'); and for the *msrA* gene: MsrA-1 (5' GCA CTT ATT GGG GGT AAT GG3') and MsrA-2 (5'GTC TAT AAG TGC TCT ATC GTG 3'). The *erm(X)* gene amplification was performed according to the protocol described by Rosato, *et al.* [10]. For all other genes we applied PCR conditions previously reported for *Streptococcus sp* [13]. The amplification products were detected by electrophoresis in 2% agarose. The size of the amplicons was estimated using commercial molecular weight ladder (BioRad Laboratories, Hercules, CA).

### Pulsed-field gel electrophoresis (PFGE)

For further characterization of *C. striatum* isolates, we used the PFGE macro-restriction analysis with XbaI as previously described [5]. Macro-restriction fragments were separated on 1% (wt/vol) ultrapure agarose gels at 6V/Cm, for 18h at 14°C with pulse times of 0.1-5 s on CHEF-DR® III. Lambda DNA concatemers were used as molecular size markers. Similarities among macro-restriction pattern were identified according to established criteria.

### Results

A total of 85 *C. striatum* strains were isolated from different specimens (Table 1). The API Coryne often provided ambiguous results and could not differentiate between *C. striatum* and other related

species such as *C. amycolatum*, *C. aurimucosum*, *C. minutissimum* and *C. simulans*. However, in the MALDI-TOF-MS method the strains were identified with cut off  $\geq 99.99$ . Screening test for sensitivity to erythromycin and clindamycin was performed using the disc diffusion method. MIC determinations for erythromycin and clindamycin with microdilution method confirmed the results of the disc diffusion method.

Resistance to examined antibiotics was observed in approximately 80% of the strains, ten of which appeared to be resistant only to one antibiotic: seven were resistant to clindamycin, while three were resistant to erythromycin. Fifty-three strains showed resistance to both antibiotics (Table 2). The shape of the growth inhibition zones indicated the presence of a constitutive MLSB resistance type.

The bacterial DNA of all 85 strains was amplified with primers for resistance genes to macrolide and lincosamide antibiotics. In 62 out of 85, the *erm(X)* gene was present. The amplification product of *erm(B)* gene was detected in 21 *C. striatum* strains, and in 12 strains both *erm(X)* and *erm(B)* amplicons were detected. There was a high correlation between the resistance to erythromycin and clindamycin and the presence of *erm(X)* gene in 85.50% and 89.65% respectively (Figure 1). Whereas, the *erm(B)* gene was detected in 26.68% and 20.68% of the strains resistant to erythromycin and clindamycin respectively (Figure 1). No amplification products of other tested genes were detected in any of the studied strains (Table 3). Although they showed resistance to macrolide and clindamycin, no amplification products were detected in 3 strains.

PFGE analysis indicated that the 85 *C. striatum* isolates represented 18 distinct strain types (data not shown), with the forty ERY-susceptible strains being distinct from the ERY resistant strain types. Ten strains resistant to erythromycin, isolated from the same ward in the same period, belonged to the same clone.

### Discussion

The genus *Corynebacterium* includes a high number of species that are usually isolated from human skin as saprophytes. However, these microorganisms have also been reported as infectious agents in a broad group of patients and have showed broad-spectrum resistance.

**Table 1.** Isolated strains of *C. striatum* (n = 85) from various infection sites

Source	Number of species	Percentage %
Wound swab	20	23.53%
blood	3	3.53%
Eye conjunctival swab	7	8.23%
Ear swab	15	17.65%
Sputum	5	5.89%
Urine	9	10.58%
Vaginal swab	8	9.41%
Tracheostomy secretion	6	7.06%
Catheter injection site	4	4.70%
Sperm	3	3.53%
Medical devices	5	5.89%

**Table 2.** Susceptibility of 85 *C. striatum* strains studied to MLS antibiotics

Antibiotics	Range (µg/ml)	Susceptibility, number of strains (%)		
		S	I	R
Erythromycin	0.06-64	14	2	69
Clindamycin	0.06-64	7	20	58

S: Susceptible, R: Resistant, I: Intermediate

**Table 3.** Antibiotic susceptibility patterns of *C. striatum* resistant isolates and their genotypes

E and Cln susceptibility phenotype (MIC)	N° of strains (%)	Genes		
		<i>ermX</i>	<i>ermB</i>	<i>mefA-E, mphA, msrA</i>
E <sup>R</sup> Cln <sup>R</sup>	53 (62.35%)	50	12	-
E <sup>R</sup> Cln <sup>S</sup>	7 (8.23%)	6	1	-
E <sup>S</sup> Cln <sup>R</sup>	3 (3.52%)	1	0	-
E <sup>I</sup> Cln <sup>R</sup>	2 (2.35%)	1	0	-
E <sup>R</sup> Cln <sup>I</sup>	9 (10.58)	3	5	-
E <sup>S</sup> Cln <sup>I</sup>	11(12.94%)	1	3	-
Total	85 (100%)	62	21	0

E<sup>R</sup> Cln<sup>R</sup>, erythromycin and clindamycin-resistant strains.


E<sup>R</sup> Cln<sup>S</sup>, erythromycin-resistant and clindamycin-susceptible strains.

E<sup>S</sup> Cln<sup>R</sup>, erythromycin-susceptible and clindamycin-resistant strains.

E<sup>R</sup> Cln<sup>I</sup>, erythromycin-resistant and clindamycin- intermediate susceptibility strains.

E<sup>I</sup> Cln<sup>R</sup>, erythromycin-intermediate susceptibility and clindamycin-resistant strains

E<sup>S</sup> Cln<sup>I</sup>, erythromycin-susceptible and clindamycin-intermediate susceptibility strains



**Figure 1.** Distribution of *erm(X)* and *erm(B)* genes among *C. striatum* strains according to the antimicrobial agents tested: (a) Erythromycin; (b) Clindamycin

In this study, including 85 strains of *C. striatum* derived from a variety of infections in humans, the use of conventional method based on the morphological and biochemical traits (Api Coryne strips) proved to be insufficient and only the application of the MALDI-TOF/VITEK method allowed the correct identification of the strains.

The *C. striatum* strains studied showed high resistance to macrolides of (81.17%), a fact that confirms the previously reported high prevalence of resistance among *Corynebacterium* species [10,11,14,15]. Clindamycin showed low activity against *C. striatum* strains (67.44%). The activity of erythromycin and clindamycin was almost identical. Among *Corynebacterium* species, the most frequently described macrolide resistance mechanism is the presence of methylase enzymes codified by *erm(X)* class genes.

The results obtained in our study confirm the high prevalence of the *erm(X)* genes and the correlation between the presence of this amplicon and the MLSB phenotype was higher than 80%. Three strains showed an MLSB resistance phenotype despite being negative for all genes tested. This must be due to the presence of the other resistance mechanisms. In this sense, mutations in 23S rRNA domain V and alterations of protein L4 and L22 have originated an MLSB resistance phenotype [16-19].

The amplification products of the *erm(B)* gene were detected in 21 (24.70%) strains. The presence of this gene has already been described in group A *Corynebacterium* strains [20-22]. In this study, the prevalence of this gene was higher than previously reported by Ortiz-Pérez, *et al.* [15] and Szemraj *et al.* [11].

Besides, there were 12 strains that carried the *erm(X)* and *erm(B)* genes simultaneously, a phenomenon previously detected in *C. urealyticum* and in *Staphylococcus* where the presence of several *erm* genes is very common [23].

In our study, no amplification products of the *mef(A-E)* gene were detected, although this gene has been previously reported in the genus *Corynebacterium* [22]. Other efflux pump genes such as *msr* have also been reported in this genus [24], but they were not detected in our report. PFGE analysis showed that the strains tested were genetically unrelated. The 10 resistant strains belonging to the same clone and isolated from the same ward in the same period suggested a clonal outbreak nosocomial infection.

## Conclusion

According to our data *erm(X)* is implicated in macrolide resistance for almost all the *C. striatum* strains analyzed in our study. Other resistance genes like *erm(B)* must also be implicated in this resistance, although its presence seems to be unusual in previously reported studies.

## Competing interests

None declared.

## Ethical approval

Not required.

## References

- Tarr PE, Stock F, Cooke RH, Fedorko DP, Lucey DR (2003) Multidrug-resistant corynebacterium striatum pneumonia in a heart transplant recipient. *Transpl Infect Dis* 5: 53-58. [Crossref]
- Ferndez-Ayala M, Nan N, Faris MC (2001) Vertebral osteomyelitis due to corynebacterium striatum. *Am J Med* 111: 160-167. [Crossref]
- Martin MC, Meln O, Celada MM, Alvarez J, Mandez FJ (2003) Septicaemia due to corynebacterium striatum: Molecular confirmation of entry via the skin. *J Med Microbiol* 52: 599-602. [Crossref]
- de Arriba JJ, Blanch JJ, Mateos F, Martínez-Alfaro E, Solera J (2002) Corynebacterium striatum first reported case of prosthetic valve endocarditis. *J Infect* 44: 193. [Crossref]
- Campanile F, Carretto E, Barbarini D, Grigis A, Falcone M, et al. (2009) Clonal multidrug-resistant Corynebacterium striatum strains, Italy. *Emerg Infect Dis* 15: 75-78.
- Baio PV, Mota HF, Freitas AD, Gomes DL, Ramos JN, et al. (2013) Clonal multidrug-resistant Corynebacterium striatum within a nosocomial environment, Rio de Janeiro, Brazil. *Mem Inst Oswaldo Cruz* 108: 23-29. [Crossref]
- Weisblum B (1995) Erythromycin resistance by ribosome modification. *Antimicrob Agents Chemother* 39: 577-585.
- Nakajima Y (1999) Mechanisms of bacterial resistance to macrolide antibiotics. *J Infect Chemother* 5: 61-74. [Crossref]
- Tait-kamradt A, Davies TA, Cronan M, Jacobs MR, Appelbaum PC, et al. (2000) Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. *Antimicrob Agents Chemother* 44: 2118-2125.
- Rosato AE, Lee BS, Nash KA (2001) Inducible, macrolide resistance in corynebacterium jeikeium. *Antimicrob Agents Chemother* 45: 1982-1989. [Crossref]
- Szemraj M, Kwaszewska A, Pawlak R, Szewczyk EM (2014) Macrolide, lincosamide, and streptogramin B resistance in lipophilic corynebacteria inhabiting healthy human skin. *Microb Drug Resist* 20: 404-409. [Crossref]
- Olender A (2013) Antibiotic resistance and detection of the most common mechanism of resistance (MLSB) of opportunistic corynebacterium. *Chemotherapy* 59: 294-306. [Crossref]

13. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L (1996) Detection of erythromycin-resistant determinants by PCR. *Antimicrob Agents Chemother* 40: 2562-2266.
14. Soriano F, Zapardiel J, Nieto E (1995) Antimicrobial susceptibilities of corynebacterium species and other nonspore-forming gram-positive bacilli to 18 antimicrobial agents. *Antimicrob Agents Chemother* 39: 208-214.
15. Ortiz-Pez A, Martin-de-Hijas NZ, Esteban J, Fernandez-Natal MI, Garca-Ca JI, et al. (2010) High frequency of macrolide resistance mechanisms in clinical isolates of corynebacterium species. *Microbial Drug Resist* 16: 273-277. [[Crossref](#)]
16. Weisblum B (1995) Erythromycin resistance by ribosome modification. *Antimicrob Agents Chemother* 39: 577-585.
17. Leclercq R, P Courvalin (1991) Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. *Antimicrob Agents Chemother* 35: 1267-1272. [[Crossref](#)]
18. Leclercq R, P Courvalin (1993) Mechanisms of resistance to macrolides and functionally related antibiotics. In Bryskier AJ, Butzler JP, Neu HC, Tulkens PM (Ed.), *Macrolides chemistry, pharmacology and clinical uses*. Arnette, Blackwell, Paris.
19. Wei L, Zheng Z (2013) Implication of ermCX gene of corynebacterium striatum in macrolide resistance in Beijing, China. *Bangladesh J Pharmacol* 8: 54-57
20. Yague G, Mora B, Martinez-Toldos MC, Rodriguez T, Valero PL, et al. (2005) Implication of ermX genes in macrolide- and telithromycin-resistance in *Corynebacterium jeikeium* and *corynebacterium amycolatum*. *Rev Esp Quimioter* 18: 2362-242. [[Crossref](#)]
21. Luna VA, Coates P, Eady EA, Cove JH, Nguyen TT, et al. (1999) A variety of gram-positive bacteria carry mobile mef genes. *J Antimicrob Chemother* 44: 19-25.
22. Aktas Z, Aridogan A, Kayacan CB, Aydin D (2007) Resistance to macrolide, lincosamide and streptogramin antibiotics in staphylococci isolated in Istanbul, Turkey. *J Microbiol* 45: 286-290.
23. Ojo KK, Striplin MJ, Ulep CC, Close NS, Zittle J, et al. (2006) Staphylococcus efflux msr(A) gene characterized in streptococcus, enterococcus, corynebacterium, and pseudomonas isolates. *Antimicrob Agents Chemother* 50: 1089-1091. [[Crossref](#)]
24. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, et al. (1999) Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants. *Antimicrob Agents Chemother* 43: 2823-2830.